Phathom Pharmaceuticals (PHAT) Enterprise Value (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Enterprise Value for 9 consecutive years, with -$185.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Enterprise Value fell 21.59% year-over-year to -$185.3 million; the TTM figure through Jun 2026 stood at -$185.3 million (down 21.59% YoY), while the FY2025 annual figure was -$132.8 million, up 55.74% from the prior year.
• Enterprise Value eased to -$185.3 million in Q2 2026 per PHAT's latest filing, from -$183.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$130.1 million in Q1 2023 and bottomed at -$384.3 million in Q4 2023.
• Historically, Enterprise Value has averaged -$218.3 million across 5 years, with a median of -$202.6 million in 2022.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 149.92% — and 2025, when it soared 59.11%.
• Phathom Pharmaceuticals' Enterprise Value stood at -$155.9 million in 2022, then slumped by 146.49% to -$384.3 million in 2023, then grew by 21.89% to -$300.1 million in 2024, then soared by 55.74% to -$132.8 million in 2025, then slumped by 39.53% to -$185.3 million in 2026.
• Business Quant data shows PHAT's Enterprise Value at -$185.3 million in Q2 2026, -$183.8 million in Q1 2026, and -$132.8 million in Q4 2025.